Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The most commonly used medication for type 2 diabetes, metformin, may not offer protection from bladder cancer, the findings of a new cohort study suggest.
Previous observational studies have linked metformin use with a reduction in cancer of the breast, colon, liver, lung, and pancreas, and 2 recent meta-analyses have shown an overall 30% reduction in all cancers with metformin compared with other diabetes medications. However, few data are available for bladder cancer, say Ronac Mamtani, MD, attending physician, hematology-oncology, Philadelphia Veterans Affairs Medical Center, Pennsylvania, and colleagues in their article, published online February 4 in Diabetes Care.
http://www.medscape.com/viewarticle/820378
(free registration required)
Previous observational studies have linked metformin use with a reduction in cancer of the breast, colon, liver, lung, and pancreas, and 2 recent meta-analyses have shown an overall 30% reduction in all cancers with metformin compared with other diabetes medications. However, few data are available for bladder cancer, say Ronac Mamtani, MD, attending physician, hematology-oncology, Philadelphia Veterans Affairs Medical Center, Pennsylvania, and colleagues in their article, published online February 4 in Diabetes Care.
http://www.medscape.com/viewarticle/820378
(free registration required)